{"url_path":"/sec/imux/8-k/2026-07-06/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-06","source_url":"https://www.sec.gov/Archives/edgar/data/1280776/0001193805-26-000916-index.html","accession_number":"0001193805-26-000916","cik":"0001280776","ticker":"IMUX","issuer_name":"IMMUNIC, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1280776/0001193805-26-000916-index.html","primary_entity_key":"0001280776","primary_entity_name":"IMMUNIC, INC."},"word_count":342,"has_tables":true,"body_markdown":"**Item 5.02. Departure of Directors or Certain Officers; Election\nof Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n \n\nOn June 29, 2026, Tamar Howson resigned as a member of the\nCompensation Committee of the Board of Directors (the “**Board**”) of Immunic, Inc., a Delaware corporation (the\n“**Company**”), and as a member of the Board, as Ms. Howson transitions into retirement. Ms. Howson’s\nresignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations,\npolicies, or practices. The Board and the Company are deeply grateful for Ms. Howson’s service, dedication, and contributions\nto the Company.\n\n \n\nIn connection with Ms. Howson’s resignation, on\nJuly 5, 2026, following the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Erik\nLundgren, the Company’s Chief Executive Officer, to serve as a Class II director of the Board until the 2028 annual meeting of\nstockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal. \n\n \n\nThere are no arrangements or understandings between Mr. Lundgren and\nany other person pursuant to which Mr. Lundgren was appointed as a director. Mr. Lundgren has not been appointed to serve on any committee\nof the Board. Mr. Lundgren will not receive any additional compensation for his service as a director. Mr. Lundgren is party to an employment\nagreement with the Company, which was previously disclosed by the Company in its Current Report on Form 8-K filed with the Securities\nand Exchange Commission on May 27, 2026. Other than such employment agreement and compensation arrangements in connection with his service\nas the Company’s Chief Executive Officer, there are no transactions involving Mr. Lundgren that would require disclosure under Item\n404(a) of Regulation S-K.\n\n \n\n \n\n \n\n  \n\n**SIGNATURES**\n\n** **\n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nas amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.\n\n \n\nDated: July 6, 2026\n**Immunic, Inc.**\n\n \n \n \n\n \nBy:\n*/s/ Erik Lundgren*\n\n \n \nErik Lundgren\n\n \n \nChief Executive Officer"}